Christine Mikail Cvijic - 20 Feb 2026 Form 4 Insider Report for Neurogene Inc. (NGNE)

Role: President and CFO
Signature: /s/ Donna M. Cochener as attorney-in-fact for Christine Mikail Cvijic
Issuer symbol: NGNE
Transactions as of: 20 Feb 2026
Net transactions value: $0
Form type: 4
Filing time: 24 Feb 2026, 18:49:01 UTC
Previous filing: 28 Mar 2025
Next filing: 03 Mar 2026
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Cvijic Christine Mikail	President and CFO	C/O NEUROGENE INC., 535 W 24TH STREET, 5TH FLOOR, NEW YORK	/s/ Donna M. Cochener as attorney-in-fact for Christine Mikail Cvijic	24 Feb 2026	0001543663

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	NGNE	Common Stock	Award	$0	+22,000	+24%	$0.000000	114,643	20 Feb 2026	Direct	F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	NGNE	Stock Option (Right to Buy)	Award	$0	+131,900		$0.000000	131,900	20 Feb 2026	Common Stock	131,900	$17.64	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Consist of 22,000 restricted stock units, which will vest in three equal annual installments beginning on the first anniversary of the grant date, subject to the Reporting Person's continued provision of services to the Issuer on each vesting date.
F2	Includes (a) 21,269 restricted stock units remaining from a grant of 31,900 restricted stock units granted on March 13, 2024 that vest annually in equal installments on March 13, 2025, March 13, 2026 and March 13, 2027; (b) 20,300 restricted stock units granted on March 26, 2025, which will vest annually in equal installments on March 26, 2026, March 26, 2027 and March 26, 2028; and (c) 22,000 restricted stock units granted on February 20, 2026, which will vest annually in equal installments on February 20, 2027, February 20, 2028 and February 20, 2029. Of the remaining shares, 24,000 are held jointly by the reporting person and her spouse, David Cvijic.
F3	This option represents the right to purchase 131,900 shares of the Issuer's common stock, one quarter of which will vest on the first anniversary of the grant date with the remaining three quarters vesting in equal monthly installments through the fourth anniversary of the grant date, subject to the Reporting Person's continued provision of service to the Issuer on each vesting date.